| Evaluating the IP Implications of Launching a Biosimilar |
IIR Business of Biosimilars |
2009 |
| Patent & IP Overview: Hatch-Waxman, the Patenting Process and More |
ACI FDA Boot Camp |
2009 |
| Non-Patent Exclusivity |
ACI FDA Boot Camp |
2009 |
| Understanding the 180-day Exclusivity Forfeiture Provisions of the MMA |
IIR Generic Drugs Summit |
2008 |
| Likely Competitive Effects of Follow-on Biologic Regulatory Incentives |
Federal Trade Commission Roundtable on Competition Issues Involving Follow-on Biologic Drugs |
2008 |
| Implications of Recent Developments and Trends in Litigating Paragraph IV Disputes |
CBI Paragraph IV Disputes |
2008 |
| Cross-examination of Expert Witness |
ACI Paragraph IV On Trial |
2008 |
| Non-Patent Exclusivity |
ACI FDA Boot Camp |
2008 |
| Is a Thriving Generic Drug Biotechnology Industry Just Around the Corner? |
LSI Biotechnology 2007 |
2007 |
| Innovation and Success Strategies |
iiBIG Drug Delivery 2007 |
2007 |
| Strategies for Defending Against Generic Drug Patent Challenges |
FDANews Audioconference |
2007 |
| A New Look at Orange Book Listings, Delistings and Related Challenges |
ACI Maximizing Pharmaceutical Patent Life Cycles |
2007 |
| Patent & IP Overview: Hatch-Waxman, the Patenting Process and More |
ACI FDA Boot Camp |
2007 |